Israeli medical technology company CathWorks has secured $30 million in Series C round.

The round was conducted by U.S. hedge fund sponsor Deerfield Management.

With the net aid, CathWorks will accelerate its clinical and commercial activities in the U.S. coupled with its recent FDA 510(k) clearances.

CathWorks generates approximately $5 million in revenue annually.